In melanoma patients, it was observed that low expression levels of SLC1A5 in the GSE78220_anti-PD1 and GSE106128_DCs cohorts were significantly associated with a favorable response to ICB therapy (Supplementary Figure 2B and 2C). This evidence concerns the gene SLC1A5 and melanoma.